95 results
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am
research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
29 Mar 24
Report of Foreign Private Issuer
4:30pm
research and development services on behalf of the Company. We also made direct inquiries of financial and clinical trial personnel regarding status … December 31,
Revenues
Operating expenses:
Research and development expenses, net (note 17a)
General and administrative expenses (note 17b)
Loss
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
9 Nov 23
Condensed Consolidated Financial Statements
4:30pm
Overview
Since inception, we have incurred significant losses in connection with our research and development and have not generated any revenue. We … funds to further develop our research and development programs.
Recent Developments In Israel
In October 2023, Hamas terrorists infiltrated
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
9 Nov 23
Condensed Consolidated Financial Statements
4:30pm
)
For the three months ended
For the nine months ended
September 30,
Revenues
Operating expenses:
Research and development expenses
General and administrative … Stock Exchange.
Financial Resources
The Company devotes substantially all of its efforts toward research and development activities and raising
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
13 Sep 23
Notice of Annual General Meeting of Shareholders
4:42pm
2013. Dr. Havron is a 43-year veteran of the biotechnology industry and was a member of the founding team and Director of Research and Development … diseases. During the past decade Dr. Schwartz has served as Senior Vice President, Head of Research & Development and Chief Medical Officer of ArQule Inc
6-K
EX-99.1
lxx6cmxa
11 Sep 23
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
8:00am
6-K
EX-99.1
sl8sc09wqj
1 Sep 23
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.2
jqhflxku
1 Sep 23
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
f3vd y23f
26 Jun 23
Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update
8:03am
6-K
EX-99.2
3yubt6x
16 Jun 23
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
iwavr9yp9ha
16 Jun 23
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
d2pf3x
4 Apr 23
Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates
8:05am
6-K
EX-99.1
ts0jew
31 Mar 23
Report of Foreign Private Issuer
4:30pm
424B5
mvenjtv9mqn c3if
30 Dec 22
Prospectus supplement for primary offering
4:01pm
6-K
EX-99.1
7q35psr
5 Dec 22
Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update
8:05am
6-K
EX-99.1
xro44 asjrh6g
2 Dec 22
Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.2
cslrnp c7myd798pv3y
2 Dec 22
Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.1
uqh3m3a
5 Oct 22
Notice of Annual General Meeting of Shareholders
3:00pm
6-K
EX-99.1
ktf1rway81t bft
22 Aug 22
Condensed Consolidated Financial Statements
8:08am